Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA

Cox, Graham J.; Zamb, Timothy J.; Babiuk, Lorne A.

doi:10.1128/jvi.67.9.5664-5667.1993

Cited by 319 publications

(75 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum antibody responses to gD (dark bars) were measured by neutralization and to BAV-3 by ELISA (light-shaded bars). Hurk et al, 1994), or as a DNA vaccine (Cox et al, 1993). Indeed, gD is considered to be a major target for neutralizing antibody and the glycoprotein is essential for virus entry into cells.…”

Section: Adenovirus Vectorsmentioning

confidence: 99%

“…These microparticles are generally biodegradable and can even be used for pulsatile release. Both polylactide -glycolide, and alginate particles have been shown to be effective, especially for oral delivery (McDermott et al, 1998;Bowersock et al, 1999); (3) DNA vaccines (Cox et al, 1993;Donnelly et al, 1993;Yokonama et al, 1995;Lewis et al, 1997); (4) transgenic plants (Arakawa et al, 1998); and (5) live vectors (Pastoret et al, 1988;Yilma et al, 1988). Live vectors are attractive because they can be engineered in such a way as to not only induce immunity to the vector, but if they are engineered correctly, they can induce immunity to an array of proteins encoded for by genes inserted into the vector.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adenoviruses as vectors for delivering vaccines to mucosal surfaces

Babiuk

Tikoo

2000

Journal of Biotechnology

View full text Add to dashboard Cite

Immunization of mucosal surfaces has become an attractive route of vaccine delivery because of its ability to induce mucosal immunity. Although various methods of inducing mucosal immunity are being developed, our laboratory has focused on developing adenoviruses as replication-competent and replication-incompetent vectors. The present report will summarize our progress in sequencing the entire bovine adenovirus-3 genome and identifying regions which can be deleted and subsequently used as insertion sites for foreign genes in developing recombinant viral vaccines. Using these recombinant viruses, we demonstrated the 'proof-of-principle' in developing mucosal immunity and, more importantly, inducing protection against bovine herpes virus in a natural host-cattle. Finally, we demonstrated that immunity and protection occurred even in animals that had pre-existing antibodies to the vector.

show abstract

Section: Adenovirus Vectorsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adenoviruses as vectors for delivering vaccines to mucosal surfaces

Babiuk

Tikoo

2000

Journal of Biotechnology

View full text Add to dashboard Cite

show abstract

“…DNA-based vaccines have recently been shown to induce protective immune responses against several viral agents, such as human immunodeficiency virus [4], bovine and human herpesviruses [5], hepatitis B virus [6], influenza virus [7], rabies virus [8], hepatitis C virus [9], etc. Unlike conventional vaccines employing either killed virus or purified antigens, DNA vaccination efficiently elicits cellular immune response including cytotoxic T lymphocyte (CTL) in addition to humoral immunity.…”

mentioning

confidence: 99%

Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice

Wang

Yuan

Matsumoto

et al. 2005

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

To analyze the immune responses of DNA vaccine encoded different gene fragments of severe acute respiratory syndrome coronavirus (SARS-Cov), SARS-Cov gene fragments of membrane (M), nucleocapsid (N), spike a (Sa), and spike b (Sb) proteins were cloned into pcDNA3.1 (Invitrogen) vector to form plasmids pcDNAM, pcDNAN, pcDNASa, and pcDNASb, respectively. After mice were immunized intramuscularly with pcDNAM, pcDNAN or pcDNASa-pcDNASb plasmid, blood was collected and serum was separated. Humoral immune response was detected with the enzyme-linked immunosorbent assay, and cellular immune response of SARS-Cov DNA vaccines was detected with lymphoproliferation assay and cytotoxic T lymphocyte assay. Results show that cellular and humoral immune responses can be detected after immunization with pcDNAM, pcDNAN or pcDNASa-pcDNASb plasmids in BALB/c mice. However, pcDNAM stimulated the highest cellular immune response than other plasmids, and pcDNASa-pcDNASb stimulated the highest humoral immune response in week 12. The present results not only suggest that DNA immunization with pcDNAM, pcDNAN or pcDNASa-pcDNASb could be used as potential DNA vaccination approaches to induce antibody in BALB/c mice, but also to illustrate that gene immunization with these SARS DNA vaccines different immune response characters.

show abstract

“…That year, at the annual vaccine meeting at the Cold Spring Harbor Laboratory (NY, USA), Liu et al [15], Robinson et al [16] and Weiner et al [17] gave rise to a new era for vaccination by describing the use of DNA in immunizations against influenza and HIV-1. Subsequently, many others described similar results following DNA immunization against rabies virus [18], bovine herpesvirus 1 [19] and hepatitis B surface antigen [20].…”

mentioning

confidence: 71%

DNA vaccines for targeting bacterial infections

Ingolotti

Kawalekar

Shedlock

et al. 2010

Expert Review of Vaccines

117

View full text Add to dashboard Cite

DNA vaccination has been of great interest since its discovery in the 1990s due to its ability to elicit both humoral and cellular immune responses. DNA vaccines consist of a DNA plasmid containing a transgene that encodes the sequence of a target protein from a pathogen under the control of a eukaryotic promoter. This revolutionary technology has proven to be effective in animal models and four DNA vaccine products have recently been approved for veterinary use. Although few DNA vaccines against bacterial infections have been tested, the results are encouraging. Because of their versatility, safety and simplicity a wider range of organisms can be targeted by these vaccines, which shows their potential advantages to public health. This article describes the mechanism of action of DNA vaccines and their potential use for targeting bacterial infections. In addition, it provides an updated summary of the methods used to enhance immunogenicity from codon optimization and adjuvants to delivery techniques including electroporation and use of nanoparticles.Keywords bacterial vaccine; cellular and humoral immune responses; DNA vaccine; molecular adjuvants Times have changed since Edward Jenner immunized James Phipps against smallpox in 1796 and created what years later became known as a vaccine [1]. From the first live-attenuated or killed vaccines to the era of DNA vaccines in the early 1990s, molecular biology and microbiology have aided medical research in the development of vaccines against infectious diseases, cancer, allergies and autoimmune diseases by inducing rapid and robust immune responses or by creating immune tolerance [2]. From the time of Jenner's first vaccine until the present day, there have been over 60 licensed vaccines in the USA. These vaccines come in many forms: killed microorganisms, live-attenuated microorganisms, subunits, conjugate vaccines or toxoids. Although there are no US FDA-approved DNA vaccines for use in humans, they are the newest vaccine platform currently in development and have already had success in veterinary medicine [3][4][5][6][7][8].© 2010 Expert Reviews Ltd † Author for correspondence: Tel.: +1 215 349 8591, Fax: +1 215 573 9436, dbweiner@mail.med.upenn.edu. Financial & competing interests disclosureThe authors declare possible commercial conflicts, which may include advising, consulting and collaboration, with Wyeth, Inovio, BMS, Virxsys, Ichor, Merck, Althea, Johnson & Johnson and Aldeveron. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. NIH Public Access Author ManuscriptExpert Rev Vaccines. Author manuscript; available in PMC 2011 May 1. Published in final edited form as:Expert Rev Vaccines. 2010 July ; 9(7): 747-763. doi:10.1586/erv.10.57. NIH-PA Author ManuscriptNIH-PA Author Manuscript N...

show abstract

Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA

Cited by 319 publications

References 24 publications

Adenoviruses as vectors for delivering vaccines to mucosal surfaces

Adenoviruses as vectors for delivering vaccines to mucosal surfaces

Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice

DNA vaccines for targeting bacterial infections

Contact Info

Product

Resources

About